3175 results for «378»
3175 results
Featured research - Tricuspid valve intervention: the TRIPLACE registry
17 Nov 2025 – From PCR London Valves 2025
This session features cutting-edge research on tricuspid valve interventions, including insights from the TRIPLACE registry on orthotopic TTVR thrombosis, predictive value of three-dimensional tricuspid annulus measurements for procedural outcomes, early clinical experiences with novel TTVR systems, and procedural clipping strategies based on results from the BRIGHT...
Left atrial appendage occlusion
17 Nov 2025 – From PCR London Valves 2025
This session focuses on the complexities and innovations in left atrial appendage occlusion (LAAO) procedures. It covers transesophageal ICE monitoring, challenges posed by existing atrial septal occluders, combined surgical and percutaneous approaches, and the practical experience with the Ultraseal device. These insights advance understanding of procedural...
Featured research - TAVI: Predictive tools, AI innovation and reintervention strategies
17 Nov 2025 – From PCR London Valves 2025
This session presents cutting-edge research in TAVI, covering the development of predictive models for clinical valve thrombosis, comparative analyses between self-expandable and balloon-expandable valves from the Greek TAVI registry, and the emerging role of AI-guided Heart Team decisions. It also examines outcomes of reintervention strategies following...
TAVI: complex vascular access
17 Nov 2025 – From PCR London Valves 2025
This session addresses the challenges of complex vascular access in transcatheter aortic valve implantation (TAVI). It discusses strategies for navigating difficult thoraco-abdominal aortic anatomies, managing double aortic arches, and overcoming hostile femoral access. Case studies illustrate meticulous planning and innovative solutions essential for successful TAVI in...
TAVI valve-in-valve - Challenging clinical scenarios
17 Nov 2025 – From PCR London Valves 2025
This session focuses on the complexities of valve-in-valve TAVI procedures, highlighting challenging clinical scenarios such as managing severely regurgitant rapid deployment valves and degenerated stentless bioprostheses. It provides detailed insights into overcoming procedural barriers and strategies for complex valve-in-valve transcatheter aortic valve replacement (TAVR) interventions.
TAVI: nightmare in the cathlab - Annular perforation, coronary obstruction & balloon rupture
17 Nov 2025 – From PCR London Valves 2025
This session presents critical case analyses of complicated TAVI procedures, highlighting unexpected and severe intra-procedural events such as annular perforation, leaflet modification complications, coronary obstructions, and device failures. It emphasizes prevention strategies, bailout techniques, and acute management to prepare clinicians for handling TAVI-related emergencies effectively.
TAVI: alternative access
17 Nov 2025 – From PCR London Valves 2025
This session addresses alternative access routes for TAVI in patients with challenging vascular anatomies. It includes innovative approaches such as transapical TAV-in-TAV procedures, transcaval implantation in emergency settings, and techniques for patients with hostile iliofemoral access, showcasing adaptive strategies when conventional access is not feasible.
TAVI: challenging anatomies
17 Nov 2025 – From PCR London Valves 2025
This session explores the management of challenging anatomical conditions in TAVI procedures. Topics include strategies for difficult self-expandable valve delivery angles, addressing complications occurring during and after TAVI, and approaches for patients with severe kyphosis or complex structural abnormalities such as aneurysms and septal anomalies.
Challenging mitral TEER: Barlow's disease, fibro-elastic deficiency & abnormal valve morphology
17 Nov 2025 – From PCR London Valves 2025
This session examines the feasibility and technical considerations of mitral transcatheter edge-to-edge repair (TEER) in complex anatomical and pathological scenarios. Topics include applications in Barlow's disease, fibro-elastic deficiency, congenital heart anomalies, Anderson-Fabry disease, and post-cardiac transplantation, providing valuable insights into expanding TEER indications and overcoming anatomical...
Mitral interventions in shock
17 Nov 2025 – From PCR London Valves 2025
This session highlights the intricacies of mitral valve interventions in the context of cardiogenic shock. It addresses complex cases including left-to-right shunts post septal puncture, severe ischemic mitral insufficiency with small valve anatomy, emergency mitral TEER for papillary muscle rupture, and bridging strategies to surgery.
Tricuspid valve interventions in complex scenarios - Part 2
17 Nov 2025 – From PCR London Valves 2025
This session delves into transcatheter interventions for the tricuspid valve in complex clinical scenarios. It covers techniques for native annular reduction via TEER, management of lead-related regurgitation, challenging cases of torrential regurgitation with device detachment, and innovative methods facilitating valve-in-ring implantation, enhancing procedural efficacy in tricuspid...
Distal radial approach to reaccess and recanalize the occluded radial artery
30 Apr 2021
A 56-year-old man was re-admitted with chest pain. He had been hospitalized 2 weeks before because of MI, was suffering from metastatic carcinoma with recurrent PTE, and was on long-term subcutaneous heparin...
COVID-19: safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2 (AstraZeneca/Oxford)
02 Jan 2021
Examination of the study methodology and results according to the PICOT principle, SWOT analysis and real-world applicability
Impact of intravascular imaging guidance on percutaneous coronary intervention of severely calcified lesions: The ECLIPSE trial
29 Mar 2025
Aaysha Cader provides her take on the ECLIPSE trial presented by Gregg W. Stone at ACC.25 in Chicago.

Author
Long-term beta-blocker treatment after acute myocardial infarction and preserved left ventricular ejection fraction: The REDUCE-AMI Trial
07 Apr 2024
REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.
Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

Author

Author